Ceribell, Inc.

Ceribell’s commercial business is concentrated in the United States, where it sells through a direct sales organization. The company manufactures its system in Sunnyvale, California, which makes U.S. operations central to both supply and commercialization. Its supply chain is globally exposed because Wearables are sourced from third-party manufacturers in China and Vietnam, while recorder components are procured from various suppliers before final assembly in California. The company’s FedRAMP High authorization also creates a pathway into approximately 170 Veterans Administration hospitals in the U.S. At present, the business is primarily domestic, but regulatory approvals in additional geographies or indications could broaden its footprint over time.

Ceribell’s revenue depends heavily on hospital adoption and continued subscription renewals, so slower-than-expected uptake or customer churn would directly pressure growth. The company also faces execution risk because its commercial model requires education, onboarding, and sustained clinical engagement to change hospital workflows. Supply chain concentration is a material risk: Wearables are sourced from third-party manufacturers in China and Vietnam, while final assembly occurs in Sunnyvale, so trade restrictions, supplier disruptions, or quality issues could affect availability and margins. As a medical device company, Ceribell is exposed to FDA and other regulatory changes that could delay new products or indications, and broader industry risks include reimbursement pressure, hospital budget constraints, and competition from conventional EEG systems or alternative monitoring technologies. Because the company is still loss-making and investing heavily in growth, it also faces financing and operating leverage risk if adoption or utilization does not scale as expected.